Good afternoon, and welcome to the ImmuCell Corporation's First Quarter Fiscal Year 2017 Financial Results Conference Call. All participants will be in listen-only-mode. [Operator Instructions] After today's presentation there will be an opportunity to ask questions. [Operator Instructions] Please note this event is being recorded. I would now like to turn the conference over to Adam Lowensteiner with Lytham Partners. Please go ahead.

Thank you, Chet, and I thank all of you for joining us today to review the unaudited financial results of ImmuCell Corporation for the first quarter of 2017 which ended on March 31, 2017. My name is Adam Lowensteiner with Lytham Partners. We are the Investor Relations consulting firm for ImmuCell. With us on the call representing the company today is Michael Brigham, President and CEO. At the conclusion of today's prepared remarks, we will open the call for question-and-answer session. Before Michael gets started, let me say that statements made by the management of ImmuCell during the course of this conference call that are not historical facts are considered to be forward-looking statements. The Private Securities Litigation Reform Act of 1995 provides a Safe harbor for such forward-looking statements. Words such as believe, expect, anticipate, estimate, will and other similar words or statements of expectation identify forward-looking statements. Such statements involve risks and uncertainties, including but not limited to those risks and uncertainties detailed from time-to-time in filings the company submits to the Securities and Exchange Commission. Investors are cautioned that forward-looking statements made during the course of this conference call are based on management's current expectations, and actual results could differ materially from the statements made. The company disclaims any obligations to update forward-looking statements. A more complete Safe Harbor statement was included in today's press release and the Form 10-Q that are both filed by the company. With that let me turn the call over to Michael Brigham, President and CEO of ImmuCell Corporation. Michael?

Thanks Adam and thank all of you for taking the time to participate in today's call. We set a record for total sales during the quarter, surpassing the previous high level set during the first quarter of 2015. The strong work by our enlarged sales team has nearly doubled our sales since 2012. So before I update you on the status of our investment and our investment [ph] plan, I would like to review the bottom line and top line results for the first quarter of 2017. We reported the 11th consecutive quarter of positive net operating income; we reported net income of $584,000 or $0.12 per diluted share for the first quarter, compared to $452,000 or $0.11 per diluted share for the first quarter of 2016. The 29% higher earnings in the current period, were somewhat diluted by having more shares outstanding in the current period, as a result of share issued during two equity raises during 2016. We still have less than 5 million shares outstanding today, 4.848 million shares to be more precise. Total sales during the quarter were up 19% in comparison to the first quarter of 2016. Total sales for the 12 month period ended March 31, 2017 were $10.1 million. Sales of First Defense, our lead product have increased during 22 of the past 26 quarters, in comparison to the respective periods of the prior years. The prolonged period of order backlog, which began in early 2015 and extended to the middle of 2016, disrupted our normal shipping patterns. It is important to keep this in mind as we compare 2017 results to 2016. When we were short on inventory during the first quarter of 2016, we prioritized shipments to our domestic customers and could not allocate enough product to international markets. With our…

Thank you, sir. [Operator Instructions] At this time I'm showing that we have no questions. So I would like to return the conference back to Michael Brigham for any closing remarks.

Well, I do appreciate you joining the call. I hope that means you have no questions, but certainly the Q's been filed, the press release has been filed. We'll be getting our Investor Deck up on our website if that is a good way for you to follow the story and get updates, that information's available and I appreciate your listening and have a great day everybody. Adam you want to close this out, if there are no late adds to the queue.

Yes, thanks Michael and thanks everyone for participating on today's call. We look forward to talking with you again at the conclusion of the second quarter, around August 10. And have a great day.

Thank you, gentlemen. The call has concluded. At this time you may now disconnect your lines. Take care.